flutamide has been researched along with Carcinoma in 33 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This prospective trial was undertaken to determine the benefits of the combination of bilateral orchidectomy with flutamide, both in terms of survival and quality of life for patients with advanced prostatic carcinoma." | 9.07 | The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico. ( De-la-Garza, J; Mendoza-Valdés, A; Ocampo-del-Carpio, O, 1991) |
| "Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma." | 8.78 | Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. ( Delaere, KP; Van Thillo, EL, 1991) |
| "Twelve consecutive men with disseminated prostate carcinoma were evaluated at 0, 6, and 12 months after treatment with a long acting gonadotropin-releasing hormone agonist (goserelin acetate) and an androgen antagonist (flutamide)." | 7.70 | The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. ( Bryant, C; Campbell, J; Diamond, T; Lynch, W, 1998) |
| "A series of 115 previously untreated patients displaying clinical stage C prostatic carcinoma with no evidence of distant metastases received combination therapy using the antiandrogen flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide; the average follow-up was 3." | 7.68 | Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. ( Cusan, L; Dupont, A; Emond, J; Gomez, JL; Koutsilieris, M; Labrie, F; Suburu, R, 1993) |
| "To compare the efficacy of orchiectomy alone and orchiectomy plus flutamide in treating patients with advanced carcinoma prostate." | 5.11 | Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach. ( Ansari, MS; Dogra, PN; Gupta, NP; Hemal, AK; Seth, A, 2004) |
| "Five hundred forty-six patients with advanced loco-regional (M0) or distant metastatic (M1) prostatic carcinoma treated with flutamide combined with either orchiectomy or LHRH analogues were included in this analysis." | 5.08 | PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. ( Casselman, J; Derde, MP; Kaufman, L; Mattelaer, J; Oosterlinck, W; Van Velthoven, R, 1997) |
| "This prospective trial was undertaken to determine the benefits of the combination of bilateral orchidectomy with flutamide, both in terms of survival and quality of life for patients with advanced prostatic carcinoma." | 5.07 | The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico. ( De-la-Garza, J; Mendoza-Valdés, A; Ocampo-del-Carpio, O, 1991) |
| "Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma." | 4.78 | Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. ( Delaere, KP; Van Thillo, EL, 1991) |
| "Twelve consecutive men with disseminated prostate carcinoma were evaluated at 0, 6, and 12 months after treatment with a long acting gonadotropin-releasing hormone agonist (goserelin acetate) and an androgen antagonist (flutamide)." | 3.70 | The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. ( Bryant, C; Campbell, J; Diamond, T; Lynch, W, 1998) |
| "05% BBN [N-butyl-N-(4-hydroxybutyl)nitrosamine] orally to 117 Wistar rats for 10 weeks, divided them into seven groups-control, surgical castration, finasteride (2 mg/kg), luteinizing hormone releasing hormone (LH-RH) agonist (1 mg/kg) flutamide (50 mg/kg), LH-RH agonist plus finasteride, and LH-RH agonist plus flutamide-, and then cystectomized them to investigate the incidence of bladder cancer on week 21; experiment 2: we administered 0." | 3.69 | Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. ( Akaza, H; Ami, Y; Ideyama, Y; Imada, S; Koiso, K; Takenaka, T, 1997) |
| "A series of 115 previously untreated patients displaying clinical stage C prostatic carcinoma with no evidence of distant metastases received combination therapy using the antiandrogen flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide; the average follow-up was 3." | 3.68 | Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. ( Cusan, L; Dupont, A; Emond, J; Gomez, JL; Koutsilieris, M; Labrie, F; Suburu, R, 1993) |
| " All patients received hormonal therapy with surgical castration and long-term administration of flutamide." | 2.67 | Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer. ( Pummer, K, 1991) |
| "Oxidative stress plays a role in prostate cancer (PrCa) initiation and development." | 1.37 | Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage. ( Boque, N; Calvo, A; Campion, J; Catena, R; Endermann, T; Gonzalez-Moreno, O; Milagro, F; Redrado, M; Saito, Y; Schomburg, L; Takahashi, K, 2011) |
| "The numb chin syndrome is characterized by facial numbness along the distribution of the mental branch of the trigeminal nerve." | 1.31 | Numb chin syndrome as the presenting symptom of metastatic prostate carcinoma. ( Halachmi, S; Madeb, R; Madjar, S; Nativ, O; River, Y; Wald, M, 2000) |
| "His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10." | 1.29 | Acute renal toxicity associated with suramin in the treatment of prostate cancer. ( Bergan, RC; Cooper, MR; Figg, WD; Headlee, D; Humphrey, J; Reed, E; Sartor, O; Thibault, A, 1994) |
| "Cancer of the prostate is the most frequent cancer and the second leading cause of cancer death in men in North America." | 1.29 | Large Shionogi tumors lose their responsiveness to flutamide treatment. ( Chen, C; Labrie, F; Poulin, R, 1996) |
| "Lymphangitic carcinomatosis of the lung is a late and often fatal manifestation of cancer." | 1.28 | Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report. ( Baldelli, S; Cellerino, R; Menichetti, ET; Miseria, S; Murer, B; Torresi, U; Tummarello, D, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 23 (69.70) | 18.2507 |
| 2000's | 5 (15.15) | 29.6817 |
| 2010's | 3 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahlman, A | 1 |
| Edsjö, A | 1 |
| Halldén, C | 1 |
| Persson, JL | 1 |
| Fine, SW | 1 |
| Lilja, H | 1 |
| Gerald, W | 1 |
| Bjartell, A | 1 |
| Kawabata, R | 1 |
| Oie, S | 1 |
| Oka, T | 1 |
| Takahashi, M | 1 |
| Kanayama, H | 1 |
| Itoh, K | 1 |
| Gonzalez-Moreno, O | 1 |
| Boque, N | 1 |
| Redrado, M | 1 |
| Milagro, F | 1 |
| Campion, J | 1 |
| Endermann, T | 1 |
| Takahashi, K | 1 |
| Saito, Y | 1 |
| Catena, R | 1 |
| Schomburg, L | 1 |
| Calvo, A | 1 |
| Ansari, MS | 1 |
| Gupta, NP | 1 |
| Hemal, AK | 1 |
| Dogra, PN | 1 |
| Seth, A | 1 |
| Wang, Y | 1 |
| Yang, J | 1 |
| Gao, Y | 1 |
| Dong, LJ | 1 |
| Liu, S | 1 |
| Yao, Z | 1 |
| Lin, CJ | 1 |
| Hsieh, RK | 1 |
| Lim, KH | 1 |
| Chen, HH | 1 |
| Cheng, YC | 1 |
| Wu, CJ | 1 |
| van der Vange, N | 1 |
| Greggi, S | 1 |
| Burger, CW | 1 |
| Kenemans, P | 1 |
| Vermorken, JB | 1 |
| Jindal, PK | 1 |
| Hota, D | 1 |
| Prasad, KV | 1 |
| Nijhawan, R | 1 |
| Vaidyanathan, S | 1 |
| Figg, WD | 1 |
| Cooper, MR | 1 |
| Thibault, A | 1 |
| Headlee, D | 1 |
| Humphrey, J | 1 |
| Bergan, RC | 1 |
| Reed, E | 1 |
| Sartor, O | 1 |
| Vailancourt, L | 1 |
| Ttu, B | 1 |
| Fradet, Y | 1 |
| Dupont, A | 3 |
| Gomez, J | 1 |
| Cusan, L | 2 |
| Suburu, ER | 1 |
| Diamond, P | 1 |
| Candas, B | 1 |
| Labrie, F | 4 |
| Bennett, CL | 1 |
| Matchar, D | 1 |
| McCrory, D | 1 |
| McLeod, DG | 1 |
| Crawford, ED | 1 |
| Hillner, BE | 1 |
| Chen, C | 1 |
| Poulin, R | 1 |
| Imada, S | 1 |
| Akaza, H | 1 |
| Ami, Y | 1 |
| Koiso, K | 1 |
| Ideyama, Y | 1 |
| Takenaka, T | 1 |
| Boccon-Gibod, L | 1 |
| Fournier, G | 1 |
| Bottet, P | 1 |
| Marechal, JM | 1 |
| Guiter, J | 1 |
| Rischman, P | 1 |
| Hubert, J | 1 |
| Soret, JY | 1 |
| Mangin, P | 1 |
| Mallo, C | 1 |
| Fraysse, CE | 1 |
| Oosterlinck, W | 1 |
| Mattelaer, J | 1 |
| Casselman, J | 1 |
| Van Velthoven, R | 1 |
| Derde, MP | 1 |
| Kaufman, L | 1 |
| Denis, LJ | 2 |
| Keuppens, F | 2 |
| Smith, PH | 2 |
| Whelan, P | 1 |
| de Moura, JL | 2 |
| Newling, D | 1 |
| Bono, A | 2 |
| Sylvester, R | 2 |
| Yokote, R | 1 |
| Tokura, Y | 1 |
| Igarashi, N | 1 |
| Ishikawa, O | 1 |
| Miyachi, Y | 1 |
| Diamond, T | 1 |
| Campbell, J | 1 |
| Bryant, C | 1 |
| Lynch, W | 1 |
| Gomez, JL | 1 |
| Koutsilieris, M | 1 |
| Suburu, R | 1 |
| Emond, J | 1 |
| Kirby, R | 1 |
| Robertson, C | 1 |
| Turkes, A | 1 |
| Griffiths, K | 1 |
| Boyle, P | 1 |
| Altwein, J | 1 |
| Schröder, F | 1 |
| Halachmi, S | 1 |
| Madeb, R | 1 |
| Madjar, S | 1 |
| Wald, M | 1 |
| River, Y | 1 |
| Nativ, O | 1 |
| Matsuda, T | 1 |
| Junicho, A | 1 |
| Yamamoto, T | 1 |
| Kishi, H | 1 |
| Korkmaz, K | 1 |
| Saatcioglu, F | 1 |
| Fuse, H | 1 |
| Muraguchi, A | 1 |
| Long, JP | 1 |
| Prout, GR | 1 |
| Miseria, S | 1 |
| Torresi, U | 1 |
| Menichetti, ET | 1 |
| Tummarello, D | 1 |
| Baldelli, S | 1 |
| Murer, B | 1 |
| Cellerino, R | 1 |
| Jurincic, CD | 1 |
| Horlbeck, R | 1 |
| Klippel, KF | 1 |
| Murphy, WM | 1 |
| Soloway, MS | 1 |
| Barrows, GH | 1 |
| Delaere, KP | 1 |
| Van Thillo, EL | 1 |
| Mendoza-Valdés, A | 1 |
| Ocampo-del-Carpio, O | 1 |
| De-la-Garza, J | 1 |
| Pummer, K | 1 |
| Denis, L | 1 |
| Newling, DW | 1 |
| Robinson, M | 1 |
| Mahler, C | 1 |
| De Pauw, M | 1 |
| Pavone-Macaluso, M | 1 |
| Cacciatore, M | 1 |
| Daricello, G | 1 |
| Pavone, C | 1 |
| Serretta, V | 1 |
| St-Arnaud, R | 1 |
| Lachance, R | 1 |
| de Kernion, JN | 1 |
| Murphy, GP | 1 |
| Priore, R | 1 |
1 review available for flutamide and Carcinoma
| Article | Year |
|---|---|
Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Remis | 1991 |
11 trials available for flutamide and Carcinoma
| Article | Year |
|---|---|
Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma; Combined Modality Therapy; Flut | 2004 |
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.
Topics: Adult; Aged; Androgen Antagonists; Carcinoma; Flutamide; Gonadotropin-Releasing Hormone; Humans; Mal | 1996 |
Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Flushing; | 1997 |
PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Belgium; Carcinom | 1997 |
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 1998 |
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antin | 1999 |
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Flutamide; Follow-Up Stu | 1991 |
The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Combined Modality Therapy; Flutamide; Humans; Male; Mexic | 1991 |
Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Epirubicin; Fl | 1991 |
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Topics: Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busereli | 1990 |
Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer.
Topics: Anilides; Carcinoma; Clinical Trials as Topic; Estramustine; Flutamide; Hematologic Diseases; Humans | 1988 |
21 other studies available for flutamide and Carcinoma
| Article | Year |
|---|---|
Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Carcinoma; Epigenesis, Genetic; Flutamide; Gene Expre | 2010 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug E | 2011 |
Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage.
Topics: Androgen Antagonists; Carcinoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Down-Regulation; | 2011 |
Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma.
Topics: Androgen Receptor Antagonists; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; | 2007 |
Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2007 |
Experience with hormonal therapy in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Es | 1995 |
Advanced prostatic carcinoma in a 19-year-old male.
Topics: Adult; Carcinoma; Combined Modality Therapy; Flutamide; Humans; Interferon alpha-2; Interferon-alpha | 1994 |
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Th | 1994 |
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Cost-Benefit Analysis; Disease Pro | 1996 |
Large Shionogi tumors lose their responsiveness to flutamide treatment.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Division; Flutamide; Humans; Male; Mice; N | 1996 |
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
Topics: Administration, Oral; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic | 1997 |
Photosensitive drug eruption induced by flutamide.
Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy, Needle; Carcinoma; Dermatitis, Photoallergic; Diagnos | 1998 |
The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Antineoplastic A | 1998 |
Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Drug Ther | 1993 |
Numb chin syndrome as the presenting symptom of metastatic prostate carcinoma.
Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma; Chin; Drug Therapy, Combination; Flutamide | 2000 |
Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Dihydrotestosterone; DNA- | 2001 |
The usefulness of serum acid phosphatase in monitoring patients with advanced prostate carcinoma.
Topics: Alkaline Phosphatase; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Cyclophosphamide; Estramustine; | 1992 |
Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report.
Topics: Buserelin; Carcinoma; Flutamide; Goserelin; Humans; Lung Neoplasms; Lymphangitis; Male; Middle Aged; | 1991 |
Pathologic changes associated with androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgens; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Drug Therapy, Combinat | 1991 |
Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
Topics: Androgen Antagonists; Carcinoma; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neop | 1990 |
Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
Topics: Androgen Antagonists; Anilides; Carcinoma; Castration; Flutamide; Glycoprotein Hormones, alpha Subun | 1986 |